<DOC>
	<DOC>NCT01318499</DOC>
	<brief_summary>The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.</brief_summary>
	<brief_title>Nepafenac 0.3% Two Study</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens; Patients who, in the opinion of the Investigator, would have improvement in bestcorrected visual acuity after surgery; Able to understand and sign an informed consent; Other protocoldefined inclusion criteria may apply. Use of topical ocular, inhaled or systemic nonsteroidal antiinflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit; Use of topical ocular, inhaled or systemic steroids within 14 days prior to surgery and through study exit; History of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye; Diabetic retinopathy in the operative eye; Known or suspected allergy or hypersensitivity to nonsteroidal antiinflammatory drugs (NSAIDs), or to any component of the test article; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>cataract</keyword>
	<keyword>inflammation</keyword>
	<keyword>pain</keyword>
	<keyword>inflammatory cells</keyword>
	<keyword>aqueous flare</keyword>
</DOC>